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482Background: The California Technology Assessment Forum is dedicated to assessment and public reporting of
syntheses of available data on medical technologies. In this assessment, transcatheter aortic valve replacement
(TAVR) was evaluated for patients with severe aortic stenosis (AS) who are at high risk for complications.
Methods and Results: In this assessment, 5 criteriawere used:Regulatory approval, sufficient scientific evidence
to allow conclusions on effectiveness, evidence that the technology improves net health outcomes, evidence that
the technology is as beneficial as established methods, and availability of the technology outside investigational
settings. In this assessment, all 5 criteria were judged to have beenmet. The primary benefit of TAVR is the ability
to treat AS in patients whowould otherwise be ineligible for surgical aortic valve replacement. It may also be use-
ful for patients at high surgical risk by potentially reducing periprocedural complications and avoiding the
morbidity and recovery from undergoing heart surgery. Potential harms include the need for conversion to an
open procedure, perioperative death, myocardial infarction, stroke, bleeding, valve embolization, aortic regurgi-
tation, heart block that requires a permanent pacemaker, renal failure, pulmonary failure, and major vascular
complications such as cardiac perforation or arterial dissection. Potential long-term harms include death, stroke,
valve failure or clotting, and endocarditis. As highlighted at the February 2012California TechnologyAssessment
Forum meeting, the dispersion of this technology to new centers across the United States must proceed with
careful thought given to training and proctoring multidisciplinary teams to become new centers of excellence.
Conclusions: TAVR is a potentially lifesaving procedure that may improve quality of life for patients at high risk
for surgical AVR. However, attention needs to be paid to appropriate patient selection, their preoperative
evaluation, surgical techniques, and postoperative care to preserve and improve on the results attained in the
Placement of Aortic Transcatheter Valve trial. Specialty societies are collaborating to ensure that this happens
in a rational and comprehensive manner. (J Thorac Cardiovasc Surg 2014;148:482-91)Supplemental material is available online.The California Technology Assessment Forum (CTAF) is
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The assessment process involves a thorough literature
review and determination of comparative effectiveness
and value of different care options. In the assessment of
transcatheter aortic valve replacement (TAVR) for patients
with severe aortic stenosis (AS) who are at high risk for
complications, 5 criteria were used: regulatory approval,
sufficient scientific evidence to allow conclusions on
effectiveness, evidence that the technology improves net
health outcomes, evidence that the technology is as
beneficial as established methods, and availability of the
technology outside investigational settings.
Drafts of technology assessments are posted for public
comment and reviewed at an open forum where input is
taken from consumers, payors, industry representatives,
and relevant health care provider organizations. The
American Association of Thoracic Surgery (AATS) hasery c August 2014
Abbreviations and Acronyms
AS ¼ aortic stenosis
CI ¼ confidence interval
CTAF ¼ California Technology Assessment
Forum
DARE ¼ Database of Abstracts of Reviews of
Effects
EuroSCORE ¼ European System for Cardiac
Operative Risk Evaluation
FDA ¼ US Food and Drug Administration
ICU ¼ intensive care unit
KCCQ ¼ Kansas City Cardiomyopathy
Questionnaire
MI ¼ myocardial infarction
NYHA ¼ New York Heart Association
OR ¼ odds ratio
PARTNER ¼ Placement of Aortic Transcatheter
Valve Trial
SAVR ¼ surgical aortic valve replacement
SF-12 ¼ Short Form 12
STS PROM ¼ Society of Thoracic Surgeons
Predicted Risk of Mortality
TAVR ¼ transcatheter aortic valve
replacement
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Dbeen an active participant in the reviews relevant to our
specialty, and the following technology assessment of
TAVR was approved by the AATS representative, Dr Frank
Sellke, as well as the AATS Council.
The primary benefit of TAVR is the ability to treat AS in
patients who would otherwise be ineligible for surgical
aortic valve replacement (SAVR). It may also be useful
for patients at high surgical risk by potentially reducing
periprocedural complications and avoiding the morbidity
and recovery from undergoing heart surgery. Potential
harms include the need for conversion to an open procedure,
perioperative death, myocardial infarction (MI), stroke,
bleeding, valve embolization, aortic regurgitation, heart
block that requires a permanent pacemaker, renal failure,
pulmonary failure, and major vascular complications such
as cardiac perforation or arterial dissection. Potential
long-term harms include death, stroke, valve failure or
clotting, and endocarditis. The focus of this statement is a
high-risk cohort of patients with AS, rather than inoperable
patients.TECHNOLOGYASSESSMENT
Technology Assessment Criterion 1: The Technology
Must Have Final Approval From the Appropriate
Government Regulatory Bodies
On November 2, 2011, the SAPIEN Transcatheter Heart
Valve model 9000TFX (Edwards Lifesciences, Irvine,The Journal of Thoracic and CaCalif), sizes 23 mm and 26 mm, received US Food and
Drug Administration (FDA) premarket approval for
transfemoral delivery in patients with severe, symptoma-
tic, native, aortic valve stenosis who have been
determined to be inoperable by a cardiac surgeon. On
October 19, 2012, the SAPIEN Transcatheter Heart Valve
model 9000TFX, sizes 23 mm and 26 mm, received FDA
premarket approval for transfemoral and transapical
delivery in patients with severe, symptomatic, native,
aortic valve stenosis who have been determined to be at
high risk defined as a Society of Thoracic Surgeons
predicted operative risk score of 8% or higher or are
judged by the heart team to be at 15% or higher risk of
operative mortality.
The Edwards SAPIEN Transcatheter Heart Valve, model
9000TFX is the only product approved by the FDA at this
time. Edwards will continue to monitor and evaluate the
SAPIEN valve and TAVR as a procedure via the national
Transcatheter Valve Therapy Registry. Thus, Technology
Assessment (TA) Criterion 1 was met. It should be
understood that other valves are in clinical trials and in
development, but only the SAPIEN valve has, to date,
been approved for use in the United States. However, we
take the liberty of considering TAVR in a more general
sense.
TACriterion 2: The Scientific Evidence Must Permit
Conclusions Concerning the Effectiveness of the
Technology Regarding Health Outcomes
The MEDLINE database, EMBASE, Cochrane clinical
trials database, Cochrane reviews database, and the
Database of Abstracts of Reviews of Effects (DARE) were
searched using the key words ‘‘transcatheter aortic valve
replacement’’ OR ‘‘transcatheter aortic valve implantation’’
OR ‘‘percutaneous aortic valve replacement’’ OR ‘‘Core-
Valve’’ OR ‘‘Sapien.’’ The search was performed for the
period from 1945 to January 2012. References were also
solicited from the manufacturers and local experts. The
abstracts of citations were reviewed for relevance and all
potentially relevant articles were reviewed in full. Case series
describing at least 100 patients treated with TAVR,
comparative studies with surgical therapy, and randomized
trials comparing TAVR with medical therapy were included.
The search identified 1356 potentially relevant studies
(Figure E1). After elimination of duplicate and nonrelevant
references, including reviews and animal studies, the search
identified 45 articles describing 16 case series,1-27
10 comparative trials,28-37 and 1 randomized trial.38-42 An
additional 69 early case series and 1 comparative study
were excluded because they were too small to provide
reliable estimates of the outcomes of interest.15,18,20,43-107
Two of the publications included with the case series6,7
and 1 of the publications included with the comparative
studies33 were meta-analyses of previous literaturerdiovascular Surgery c Volume 148, Number 2 483
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described in this assessment. Thus, TA Criterion 2 was met.TA Criterion 3: The Technology Must Improve Net
Health Outcomes
Symptomatic AS has a high short-term mortality so total
mortality should be the primary outcome of interest.
Treatment of AS is associated with an increased risk for
stroke and some patients perceive that their quality of life
living with the disabilities of a stroke could be worse than
death, so stroke risk is a key outcome. Quality of life and
functional status are also major concerns. The New York
Heart Association (NYHA) developed the system that is
most commonly used to quantify the degree of functional
limitation imposed by heart disease.108 Two more detailed
quality of life questionnaires, the Kansas City Cardio-
myopathy Questionnaire (KCCQ) and the Medical
Outcomes Study Short Form 12 (SF-12) were used in
some of the studies. The KCCQ is a validated 23-item
questionnaire focusing on 5 domains: symptoms, physical
limitation, social limitation, self-efficacy, and quality of
life.109,110 Other important periprocedural and longer-term
outcomes include MI, major bleeding, kidney injury, major
vascular complications, and valve dysfunction including
aortic regurgitation. A consensus panel published clear
definitions for these outcomes in 2011.111 Table E1
describes when and where the studies were performed,
which valve type was used, and a brief summary of the
characteristics of the patients in the studies.
The procedural success rate was generally high, ranging
from 95% to 99% in the most recent series. Table E2
summarizes the procedural outcomes and events over 30
days. The most important outcome, 30-day mortality, varied
from 6% to 19%, likely due to differences in the underlying
risk of the different patient groups studied. The risk of major
stroke varied from 1% to 5%. TAVR is known to cause
some arrhythmias and 2% and 39% of patients in these
case series required insertion of a permanent pacemaker.
Case series that evaluated both the CoreValve (Medtronic,
Minneapolis, Minn) and the SAPIEN valve suggested that
the requirement for a pacemaker is more common with
the CoreValve.14,18,25 Major vascular complications varied
widely (2% to 28%), in part because of differences in
what was classified as a vascular complication. Aortic
regurgitation, both around and through the implanted
valve, is a common complication but most are trivial to
mild and unlikely to cause symptoms. However, the
prevalence of moderate to severe aortic regurgitation has
been reported to be between 2% and 26% in these case
series. The rates of MIs, valve embolization, and cardiac
tamponade were generally low (<1%). The need for
repeat interventions on the implanted valve was between
1% and 3%, but these data were not consistently484 The Journal of Thoracic and Cardiovascular Surgreported.12,25 Table E3 summarizes the outcomes at
1 year including quality of life outcomes.
Gilard and colleagues5 published data from the largest
prospective cohort study ofTAVR in 2012. The FrenchAortic
National CoreValve and Edwards (FRANCE 2) Registry
collected data on 3195 patients treated between January
2010 and October 2011. The average age of the patients
was 83 years and half were women. The treating physicians
used the SAPIEN valve for 67% of patients and the
CoreValve for the remaining 33%. They used the trans-
femoral approach for 75% of patients and the transapical
approach for 18%. The PARTNER randomized trials, as
well as observational studies, identified stroke, paravalvular
aortic regurgitation, and the need for permanent pacemaker
placement as important harms associated with TAVR.112
These outcomes were emphasized in this FRANCE 2
Registry publication.5 After 1 year of follow-up in the
FRANCE2Registry, the incidence of strokewas 4.1%. After
30 days, new pacemakers were placed in 16% of patients and
paravalvular leaks were observed in 64% of patients,
althoughonly16%weremoderate or severe.Newpacemaker
placement was more common with the CoreValve than the
SAPIEN device (24% vs 12%). Mortality was lower with
the transfemoral approach than the transapical approach at
30 days (8.5% vs 14%) and at 1 year (17% vs 22%). In a
multivariable analysis adjusting for baseline risk factors,
factors associated with an increased mortality at 1 year
included, as expected, both a higher logistic EuroSCORE
(European System for Cardiac Operative Risk Evaluation)
and a higherNYHAfunctional class, aswell as the transapical
approach and moderate to severe paravalvular regurgitation.
This supports the hypothesis that the transfemoral approach
should be the preferred approach if it is technically feasible,
and that advances in valve design and delivery that reduce
the incidence of paravalvular regurgitation may reduce
mortality at 1 year and beyond.
Comparative studies with SAVR. Ten studies compared
the outcomes in high-risk patients with symptomatic AS
referred for TAVR with patients who were treated with
SAVR.28-37 The patient characteristics and the primary
outcomes of the studies are summarized in Tables E1 to
E3. Most of these studies were retrospective. The
investigators used a variety of approaches to attempt to
account for baseline differences between patients treated
with TAVR and those treated with SAVR (n ¼ 1008)
including matching, multivariable regression, and
propensity score techniques both for adjustment and
matching. The results of the earliest study by Piazza and
colleagues34 are instructive. Patients in the TAVR group
(n¼ 114) were significantly older, had higher NYHA class,
and were at much higher operative risk according to the
logistic EuroSCORE than those in the SAVR group
(n ¼ 1008). As would be expected based on those
differences, the 30-day mortality was substantially higherery c August 2014
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95% confidence interval [CI], 2.2-9.6). Using different
logistic regression models to control for confounding gave
a range for results from 1 analysis suggesting that TAVR
may be superior to SAVR (adjusted OR, 0.60; 95% CI,
0.11-3.36) to another suggesting that outcomes with
TAVR may be much worse (adjusted OR, 7.6; 95% CI,
0.9-63). Using propensity scores, the models ranged from
an adjusted OR of 0.35 (95% CI, 0.04-2.7) to an adjusted
OR of 3.2 (95% CI, 0.3-32). All the confidence intervals
included 1 but the confidence intervals were wide and the
adjusted ORs varied widely by the choice of modeling
technique. This highlights the difficulty in appropriately
and fully adjusting for confounding in observational studies
like this and demonstrates why it was appropriate to require
randomized trials to evaluate the relative benefits and harms
of TAVR both for inoperable and high-risk patients.
Jilaihawi and colleagues33 published a meta-analysis
comparing outcomes in 5025 high-risk patients with severe
AS treated with TAVR (16 studies) to those of 3512 patients
treated with SAVR (19 studies). Although the number of
patients is impressive, the investigators simply pooled the
data from these disparate studies without appropriate
meta-analytical techniques. Undoubtedly, there was
significant heterogeneity between the studies that were
pooled as was described in the meta-analysis by Genereux
and colleagues.6 Furthermore, patients from the 2 groups
most often were not treated at the same institution or even
in the same country. It is difficult to draw any meaningful
conclusions from this study.
Four of the studies30-32,36 used propensity scores to match
patients treated with SAVR with those treated with TAVR
and 1 matched on baseline characteristics35 (age, logistic
EuroSCORE, coronary artery disease, valvular heart
disease). In general, these studies found that patients in
the TAVR group had shorter procedural times, spent fewer
days in the intensive care unit, and had shorter hospital
stays. There were no significant differences in 30-day
mortality and stroke rates. Patients in the TAVR group
required permanent pacemakers more often and had a
higher incidence of paravalvular aortic regurgitation.
Randomized clinical trials. The Placement of Aortic
Transcatheter Valve Trial. The PARTNER (Placement of
Aortic Transcatheter Valve Trial)113 included 2 parallel,
randomized clinical trials, 1 in operable, high-risk
patients (PARTNER A)38-42 and 1 in patients ineligible
for surgery (PARTNER B).113-115 This technology
assessment focuses on the PARTNER A trial because
our February 2012 CTAF assessment112 focused on the
PARTNER B trial and the use of TAVR for patients
ineligible for SAVR.
Patients were considered at high risk for operative
complications or death if they had a predicted probability
of death within 30 days of surgery of at least 15% asThe Journal of Thoracic and Cadetermined by surgeons at each center.42 A Society of
Thoracic Surgeons (STS) predicted risk of mortality
(PROM) score of at least 10% was used as a guideline for
high risk. Patients were required to have severe AS defined
by either an aortic valve area of less than 0.8 cm2, an aortic
valve gradient of at least 40 mm Hg, or a peak aortic jet
velocity of at least 4.0 m/s. They also were required to
have NYHA class II, III, or IV symptoms. Patients were
excluded if they had a bicuspid or noncalcified aortic valve,
acute MI, coronary artery disease requiring revasculariza-
tion, left ventricular ejection fraction less than 20%, severe
mitral or aortic regurgitation, transient ischemic attack
or stroke in the previous 6 months, or severe renal
insufficiency (creatinine>3.0 mg/dL or preoperative renal
replacement). Eligible patients were randomized to receive
the Edwards SAPIEN heart valve system (transfemoral or
transapical) or SAVR. The primary end point of the trial
was death from any cause.
The study characteristics and findings are summarized in
Tables E1 to E3. In brief, 348 patients were randomized to
the TAVR group and 351 to the SAVR group. Follow-up was
100% complete over 2 years and the primary analysis was
done according to strict intention-to-treat principles. No
blinding was reported and no sham procedure was
performed.
The average age of the participants was 84 years and
43% were female. Their predicted operative mortality by
the logistic EuroSCORE was 28% and by the STS PROM
score was 12%. There were no significant differences
between the 2 groups on 26 potential confounders at
baseline although there was a trend towards more patients
with an increased creatinine level in the TAVR group
(11% vs 7%, P ¼ .06). An increased creatinine level has
been associated with higher mortality in observational
studies of aortic valve replacement so this difference would
tend to bias results against TAVR.
TAVR was successful for 95% of patients in the TAVR
group. Three patients died during the procedure and it
was aborted or converted to open surgery in 16 patients
(4.6%). More than 1 transcatheter valve was implanted in
7 patients. The reasons for the use of multiple valves
included valve embolization (2 patients) and residual aortic
regurgitation (5 patients). Three of these 7 patients died.
Valve embolization occurred in 7 additional patients.
The procedure was aborted in 2 patients and converted to
an open procedure in the remaining 7. As expected, the
procedure time was shorter for TAVR (133 minutes vs
230 minutes, P values not reported) as was the average
stay in the intensive care unit (ICU) after the procedure
(3 days vs 5 days, P values not reported) and the length of
the initial hospitalization (8 days vs 12 days, P values not
reported).
At 30 days, there were no differences in death from any
cause (3.4% vs 6.5%, P ¼ .07), major strokes (3.8% vsrdiovascular Surgery c Volume 148, Number 2 485
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8.2%, P¼ .52). The TAVR group did have more neurologic
events including transient ischemic attacks and minor
strokes (5.5% vs 2.4%, P ¼ .04). The TAVR group had
more major vascular complications defined as aortic
dissection, left ventricular perforation, embolization
resulting in permanent damage, vascular injury requiring
surgical intervention or causing death, permanent disability,
or blood transfusion of at least 3 units (11.0% vs 3.2%,
P < .001). However, the TAVR group had fewer major
bleeding episodes defined as bleeding leading to death or
prolonged hospitalization requiring surgical intervention
or blood transfusions of at least 3 units (9.3% vs 19.5%,
P< .001). The TAVR group also had fewer episodes of
new onset atrial fibrillation (8.6% vs 16.0%, P ¼ .006).
There were no differences in the rate of MIs, new
pacemakers, or the need for dialysis. The prevalence of
paravalvular aortic regurgitation was more common after
TAVR for both minimal disease (65% vs 25%, P<.001)
and moderate to severe regurgitation (12.1% vs 0.9%,
P < .001). More patients in the TAVR group reported
NYHA class II or lower symptoms at 30 days (72% vs
59%, P<.001).42
At 1 year the outcomes were similar. There were no
differences in death from any cause (24.2% vs 26.8%,
P ¼ .44), major strokes (5.1% vs 2.4%, P ¼ .07), or the
combination of the two (26.5% vs 28.0%, P ¼ .68). The
difference in mortality at 1 year between the 2 groups
(2.6%, 95% CI, 9.3% to þ4.1%) was within the
prespecified noninferiority boundary of 7.5% (P ¼ .001
for noninferiority). The differences in neurologic outcomes,
major vascular complications, and major bleeding
persisted. The prevalence of paravalvular aortic regurgita-
tions remained more common after TAVR for minimal
disease (60% vs 20%, P< .001) and moderate to severe
regurgitation (6.8% vs 1.9%, P<.001).
One of the major concerns raised when CTAF considered
TAVR for inoperable patients was the lack of longer-term
follow-up. The investigators published the 2-year follow-
up for the PARTNER trials in 2012.39,114 There were no
cases of structural valve deterioration and valve area was
preserved as assessed by echocardiography. There
continued to be no differences in overall mortality at
2 years (35.0% vs 33.9%, P ¼ .78), as well as no
significant differences in the rate of stroke or
rehospitalization. The Kaplan-Meier curves did not diverge
at all between 2 and 3 years of follow-up suggesting that the
result is likely to be similar over at least 3 years.
Quality of life indicators were better in the TAVR group
at 1 month but not at 6 or 12 months.41 This likely reflects a
decrement in quality of life associated with median
sternotomy. Quality of life improvements were nearly iden-
tical in the 2 groups at 6 and 12 months as measured by the
KCCQ, the SF12, the EQ-5D, and their related subscales.486 The Journal of Thoracic and Cardiovascular SurgAs noted earlier, this was a high-quality randomized trial
with remarkable 100% follow-up of all patients for 2 years.
There were no significant baseline differences between the
TAVR and SAVR groups and the only borderline difference
would be expected to bias the results against the TAVRgroup.
The primary methodological concern centers on the 42 pa-
tients who were not treated as randomized. Only 4 (1.1%)
were in the TAVR group and 38 (10.8%) were in the SAVR
group (P< .001). This could introduce selection bias. To
address this, the investigators performed a strict intention-
to-treat analysis and reported this as the primary result.
They also performed as-treated analyses for all the major
outcomes and none of the conclusions were changed. The
other concern was that the time from randomization to treat-
ment was longer for the surgical group (10.6 days vs 15.6
days, P< .001). This may explain why there were more
pre-procedural deaths in the surgical group (3 vs 10 deaths).
At 30 days, there still would be fewer deaths in the transcath-
eter group (adding 7 additional deaths to that group) but at 1
year there would have been slightly more deaths in the
transcatheter group (84 þ 7 ¼ 91 vs 89 deaths). Thus, it
does not seem that accounting for the difference in pre-
procedure deaths would change the conclusion of the study.
In summary, a high-risk surgical patient with severe AS
who was randomized to TAVR had a similar risk of dying
over 2 years of follow-up compared with SAVR. The rates
of stroke and rehospitalizationwere also equivalent, although
when all neurologic events were counted, there was a slight
excess in the TAVR group. Patients in the TAVR group expe-
rienced more major vascular events and more paravalvular
aortic regurgitation. Patients in the SAVR group experienced
moremajor bleeding and required longer stays in the ICU and
hospital after the valve replacement procedure.Quality of life
improved more rapidly in the TAVR group, likely related to
the need for a median sternotomy in the SAVR group.
However, quality of life improvements were comparable in
bothgroups at 6 and12months. There are differences in terms
of vascular complications, major bleeding, strokes, atrial
fibrillation, and aortic regurgitation but they seem to balance
each other and do not have an impact on the medium-term
outcomes over 2 to 3 years. Some uncertainty remains about
the long-term viability of the transcatheter valves so the
outcomes of the studies over 5 years of follow-up should be
closely monitored. Thus, TA Criterion 3 was met.
TA Criterion 4: The Technology Must Be as
Beneficial as Any Established Alternatives
The established alternative to TAVR for patients with
severe AS is SAVR. Because patients with severe AS are
generally older and have multiple comorbidities, they are
at high risk for complications during and after SAVR,
including death.
The randomized PARTNER A trial, described in detail
earlier, directly compared TAVR with SAVR. As discussedery c August 2014
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there were no statistically or clinically significant
differences between the 2 groups in death from any cause,
repeat hospitalizations, strokes, the combination of death
from any cause and repeat hospitalization, or the combina-
tion of death from any cause and stroke.39 There was an
absolute difference of 8% more patients having major
vascular complications with TAVR and an absolute
difference of 10% more patients having major bleeding
complications with SAVR. There were no differences
between the groups in quality of life after 1 month or in
the incidence of MI, new pacemakers, renal failure,
endocarditis, or structural valve deterioration. There was
an excess of mild and moderate paravalvular aortic
regurgitation in the TAVR group at 30 days and 1 year,
which has been associated with an increased risk for death
in previous studies. The survival curves remained
overlapping for years 1 to 3 of follow-up but there still
may be longer-term problems that arise either from the
valves themselves or from the paravalvular leaks. This
should be watched in continued long-term follow-up given
that almost two thirds of the patients in both groups were
still alive at 2 years. That said, the data are convincing
that TAVR is equivalent to SAVR in high-risk patients
for all important outcomes over 2 years. However, the
longer-term results remain to be established. Indeed, either
paravalvular or valvular aortic insufficiency, which are
increased in the TAVR group, are associated with
diminished long-term survival.
The definition of high risk is an essential part of this
conclusion. The FDA indication for the Edwards SAPIEN
device uses essentially the same definition as that used in
the inclusion criteria for the PARTNER trial: patients
should have an STS PROM score of at least 10 or have at
least a 15% risk of death within 30 days as determined by
at least 1 surgeon. There are ongoing randomized trials
evaluating the relative risks and benefits of TAVR versus
SAVR in lower-risk patients. Therefore, TA Criterion 4
was met.
TA Criterion 5: The Improvement Must Be
Attainable Outside the Investigational Setting
TAVR is a technically difficult procedure with a steep
learning curve. In the Vancouver single center case series,
outcomes improved over time.16 The investigators
compared results in the first 135 patients with the results
in the subsequent 135 patients. The overall success rate
increased from 93% to 98% and the 30-day mortality
decreased from 13% to 6%. There were fewer cases of
device embolization, coronary occlusion, stroke, and major
vascular injury in the second half of their case series.16
Some of the improvement may reflect changes in the design
of the valvular implants and their delivery systems. In
addition, patients in the second half of the case seriesThe Journal of Thoracic and Cawere at significantly lower risk for poor outcomes
(STS PROM score 8.5 vs 10.5, P < .01). Clearly, care
must be taken to ensure adequate training and proctoring
of physicians performing TAVR. Thus, although equivalent
outcomes in the investigational and noninvestigational
setting are likely, subsequent studies and analysis will be
required to confirm this.
Consensus recommendations have been made jointly by
the American College of Cardiology Foundation and the
STS.116 In brief, they recommend that programs using
TAVR should be performed at a limited number of
specialized heart centers with multidisciplinary teams that
include at least 1 interventional cardiologist and 1 cardiac
surgeon. All personnel should receive appropriate training
and credentialing and follow standard protocols set up by
expert consensus groups for evidence-based patient
selection, procedural details, and complication manage-
ment. A registry has been established to track appropriate
use and patient outcomes.116 Outcomes data from the first
year of the registry should be published in 2013 with
additional data on whether the outcomes achieved in the
PARTNER trial can be replicated in clinical practice in
the United States. If followed, these recommendations
should ensure that appropriate patients are selected and
that highly skilled teams perform the procedure. Thus, TA
Criterion 5 was met.
CONCLUSIONS
AS is common in the elderly and when symptoms arise,
about half of these patients die within 2 years. SAVR is
an effective therapy for AS that can be performed with
relatively low morbidity and mortality given the age and
comorbidity of most patients with AS. To address the
need for additional treatment options for patients with AS
who are inoperable or very high risk for surgical treatment,
2 aortic valves (Medtronic’s CoreValve and the Edwards
SAPIEN valve), which can be implanted using catheters,
have been developed. In observational studies, the success
rate for transcatheter aortic valve implantation has been
greater than 95%, but the 30-day mortality ranged from
6% to 13%. In addition, up to 39% of patients required a
permanent pacemaker, up to 28% of patients experienced
major vascular complications, and up to 42% developed
moderate to severe AS. The case series data and the compar-
ative studies gave inadequate information to fully under-
stand the relative benefits and harms of TAVR compared
with standard surgical valve replacement.
The PARTNER A trial is the pivotal randomized trial
that helps us understand the balance of risks and harms of
TAVR compared with SAVR.38-42 In the trial, 348 patients
with severe AS were randomized to the TAVR group
(Edwards SAPIEN valve via the transfemoral or
transapical approach) and 351 patients were randomized
to the surgical therapy group. Mortality over 2 yearsrdiovascular Surgery c Volume 148, Number 2 487
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of stroke, pacemaker placement, valve failure, or
rehospitalization in the TAVR group. Quality of life
measures improved faster in the TAVR group but were
essentially the same in the 2 groups by 6 months. The
excess of major vascular complications in the TAVR
group was balanced by an excess of major bleeding
episodes in the surgical group. Other features that
weigh in favor of TAVR include avoiding a median
sternotomy, a shorter stay in the ICU, and a shorter
hospitalization. The major remaining concern is the
excess of paravalvular aortic regurgitation in the TAVR
group compared with the surgical group.
The trial was not methodologically perfect. Forty-two
patients were not treated as randomized and all but 4 of
them were in the surgical group. This may have introduced
some selection bias because it represents more than 10% of
the patients randomized to the surgical group. In addition,
the time from randomization to procedure was significantly
longer in the surgical group. This may in part explain why
10 patients randomized to the surgical group died before
their procedure whereas only 3 patients in the TAVR group
died before their procedure. Intention-to-treat analyses, per
protocol analyses, and sensitivity analyses suggest that
these problems are not large enough to invalidate the
conclusion that the 2 treatments are equally beneficial, but
others may judge differently.
Patient selection is essential to ensure that the results of
the PARTNER trial apply to patients treated in the
community. A multidisciplinary team that includes at a
minimum 1 cardiac surgeon, a general cardiologist, and
an interventional cardiologist should agree that a patient
is high risk before offering TAVR. Patients must be
informed of the upfront risks of death, stroke, pacemaker
placement, and major vascular complications (11% in the
PARTNER A trial). Patients also need to be informed
that some uncertainty remains about the durability of
percutaneous aortic valves beyond 3 years. There is a
high prevalence of moderate to severe aortic regurgitation,
which may lead to recurrent symptoms or unforeseen
problems with the valve. As was highlighted at the February
2012 CTAF meeting, the dispersion of this technology to
new centers across the United States must proceed
with careful thought given to training and proctoring multi-
disciplinary teams to become new centers of excellence.
Attention needs to be paid to appropriate
patient selection, their preoperative evaluation, surgical
techniques, and postoperative care to preserve and improve
on the results attained in the PARTNER trial. As described
under TA Criterion 5, the specialty societies are
collaborating to ensure that this happens in a rational and
comprehensive manner.116488 The Journal of Thoracic and Cardiovascular SurgReferences
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FIGURE E1. Selection of studies for inclusion in the review.
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TABLE E1. Characteristics of the larger published studies on transcatheter aortic valve replacement












Grube 2008 TAVR Sieborg, Germany 136 2005-2008 CoreValve NR 82 58 23 9
Piazza 2008 TAVR Multicenter 646 2007-2008 CoreValve NR 81 23 NR
Rodes-Cabeau 2010 TAVR Canada, 6 centers 339 2005-2009 SAPIEN 8 81 55 NR 10
Bosmans 2011 TAVR Multicenter Belgium 328 ?-2010 CoreValve,
SAPIEN
NR 83 54 28 NR
D’Onofrio 2011, 2012 TAVR Multicenter Italy 566 2008-2011 SAPIEN 10 81 61 26 12
Eltchaninoff 2011 TAVR Multicenter France 244 2009 CoreValve,
SAPIEN
1 82 43 26 19







10 83 51 NR 8
Lefevre 2011 TAVR TF Multicenter 61 2007-2008 SAPIEN 12 82 61 26 11
TAVR TA Europe 69 82 51 34 12
Moat 2011 TAVR Multicenter UK 870 2007-2009 CoreValve,
SAPIEN
NR 82 48 19 NR
Tamburino 2011 TAVR Multicenter Italy 663 2007-2009 CoreValve 18 81 56 23 NR
Thomas 2010, 2011 TAVR TF Multicenter Europe 463 2007-2009 SAPIEN 12 82 55 26 NR
TAVR TA 575 81 56 29
Zahn 2011 TAVR Multicenter Germany 697 2009 CoreValve,
SAPIEN
1 81 56 21 NR
Eggebrecht 2012 TAVR MA 53 studies 10,037 2004-2011 CoreValve,
SAPIEN
1 82 53 25 NR
Genereux 2012 TAVR MA 16 studies 3519 2008-2010 CoreValve,
SAPIEN
12 NR NR 23 9
Gilard 2012 TAVR Multicenter France 3195 2010-2011 CoreValve,
SAPIEN
12 83 49 22 14
Comparative studies
Kapadia 2009 TAVR Cleveland, Ohio 18 2006-2007 SAPIEN 9 81 33 28 11
Medical 36 6 83 53 25 13
Rajani 2010 TAVR Brighton, UK 38 2007-2009 CoreValve 7 83 45 24 NR
Medical 47 81 52 13 NR
Piazza 2009 TAVR 2 European centers 114 2006-2008 1
Surgical 1008
Zierer 2009 TAVR Frankfurt, Germany 21 2006-2007 SAPIEN 12 85 71 38 NR
Surgical 30 82 63 35 NR
Clavel 2010 TAVR Multicenter Canada,
Austria
83 2006-2008 SAPIEN 12 81 41 32 12
Surgical Germany 200 70 19 18 6
Walther 2010 TAVR Leipzig, Germany 100 2006-2008 SAPIEN 12 83 77 29 15
Surgical 100 1996-2008 82 70 30 NA
Higgins 2011 TAVR British Columbia,
Canada
46 2005-2010 SAPIEN 1 78 80 NR NR
Surgical 46 2001-2009 78 79 NR NR
Stohr 2011 TAVR Aachen, Germany 175 2008-2010 CoreValve,
SAPIEN
1 80 40 21 NR
Surgical 175 79 24 17 NR
Ben-Dor 2012 TAVR PARTNER
nonrandomized
159 2007-2011 SAPIEN 13 84 57 42 12
Surgical 146 24 79 49 27 8
Medical 595 7 82 55 43 12
Conradi 2012 TAVR Hamburg, Germany 82 2009-2010 SAPIEN 6 82 63 24 9
Surgical 82 82 58 24 9
Fusari 2012 TAVR Italy 106 2008-2009 SAPIEN 21 81 68 22 8.4
Surgical 81 22 78 67 8.5 2.8
Jilaihawi 2012 TAVR MA 35 studies 5024 Before 2010 CoreValve,
SAPIEN
24 81 54 25 NR
Surgical 3512 82 56 18 NR
(Continued)
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179 2007-2009 SAPIEN 19 83 54 28 12






348 2007-2009 SAPIEN 24 84 43 29 12
Smith 2011 Surgical 351
Kodali 2012
TAVR, Transcatheter aortic valve replacement; NR, not reported; TF, transfemoral; TA, transapical; NA, not available; STS, Society of Thoracic Surgeons; EuroSCORE, European
System for Cardiac Operative Risk Evaluation; MA, meta-analysis; PARTNER, Placement of Aortic Transcatheter Valve Trial.
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Grube 2008 TAVR 86 12 1 NR 25 26 2 1 NR NR
Piazza 2008 TAVR 97 8 2 2 9 NR 1 1 0 NR
Rodes-Cabeau
2010
TAVR 93 10 2 13 5 6 1 0 NR,>1.4 3
Bosmans 2011 TAVR 97 11 5 NR NR NR NR NR NR NR
D’Onofrio 2011,
2012
TAVR 99 8 3 NR 5 NR 2 NR NR 6
Eltchaninoff 2011 TAVR 98 13 4 7 12 2 NR 2
Gurvitch 2011 TAVR 95 10 3 7 6 NR NR 2 9 3
Humphries 2011; TAVR Failures
excluded
9 2 9 6 NR NR NR 17 NR
Webb 2009
Lefevre 2011 TAVR TF 96 8 3 28 2 NR 3 NR 5 0
TAVR TA 95 19 2 5 4 6 12 6
Moat 2011 TAVR 97 7 4 6 16 14 1 NR NR NR
Tamburino 2011 TAVR 98 6 1 2 17 21 0 1 3 NR
Thomas 2010,
2011
TAVR TF 95 6 2 11 7 2 NR NR NR 1
TAVR TA 93 10 3 2 7 2 7
Zahn 2011 TAVR 98 12 3 17 39 Severe 2.3 1 2 NR NR
Eggebrecht 2012 TAVR NR 8 3 NR NR NR NR NR NR NR
Genereux 2012 TAVR 92 8 4 12 14 7 1 3 16 NR
Gilard 2012 TAVR 97 10 2 5 16 17 NR NR 4 NR
Comparative studies
Kapadia 2009 TAVR NR 5 0 NR 6 NR 0 NR NR NR
Medical NR NR NR NR NR NR NR NR NR NR
Rajani 2010 TAVR NR 8 3 3 34 NR NR 3 NR 3
Medical NR NR NR NR NR NR NR NR NR NR
Piazza 2009 TAVR 10
Surgical 2
Zierer 2009 TAVR 85 14 0 NR 0 NR NR NR NR 0
Surgical 100 10 3 NR 3 NR NR NR NR 10
Clavel 2010 TAVR NR 19 NR NR NR 6 NR NR NR NR
Surgical NR 12 NR NR NR 0 NR NR NR NR
Walther 2010 TAVR 97 10 0 NR 10 NR NR NR NR NR
Surgical 100 15 2 NR NR NR NR NR NR NR
Higgins 2011 TAVR NR 13 0 NR NR NR NR NR NR NR
Surgical NR 9 4 NR NR NR NR NR NR NR
Stohr 2011 TAVR 100 12 1 NR 15 3 NR NR NR 4
Surgical 100 8 0.5 NR 2 0 NR NR NR 14
Ben-Dor 2012 TAVR NR 12 NR NR NR NR NR NR NR NR
Surgical NR 13 NR NR NR NR NR NR NR NR
Medical NR 10 NR NR NR NR NR NR NR NR
Conradi 2012 TAVR 96 7 2 NR 4 1 NR NR NR NR
Surgical 100 9 2 NR 2 0 NR NR NR NR
Fusari 2012 TAVR 100 2 1 4 6 NR 1 1 2 5
Surgical 100 4 2 0 1 NR 1 0 5 5
Jilaihawi 2012 TAVR NR 8 3 7 12 12 1 1 NR 4
Surgical NR 9 2 NR 6 NR NR NR NR 2
(Continued)
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PARTNER B TAVR 97 5 5 16 3 12 0 NR 17 1
Leon 2010 Medical 100 3 1 1 5 - 0 NR 4 2
PARTNER A TAVR 95 3.4 3.8 11.0 3.8 12.2 0 NR 9.3 2.9
Smith 2011 Surgical 99 6.5 2.1 3.2 3.6 0.9 0.6 NR 19.5 3.0
Kodali 2012
MI, Myocardial infarction; TAVR, transcatheter aortic valve replacement;NR, not reported; TF, transfemoral; TA, transapical; PARTNER, Placement of Aortic Transcatheter Valve
Trial.
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TABLE E3. Benefits and harms of transcatheter aortic valve replacement at 1 year








Grube 2008 TAVR 18 4 3.3 to 1.7 NR NR
Piazza 2008 TAVR NR NR NR NR NR
Rodes-Cabeau 2010 TAVR 24 NR NR NR NR
Bosmans 2011 TAVR 21 NR NR NR NR
D’Onofrio 2011, 2012 TAVR 17 NR NR NR NR
Eltchaninoff 2011 TAVR NR NR NR NR NR
Gurvitch 2011 TAVR NR NR NR NR NR
Humphries 2011; Webb 2009 TAVR 83 F, 73 M NR NR NR NR
Lefevre 2011 TAVR TF 21 7 86% Class I or II 50 to 68 NR
TAVR TA 51 10 80% Class I or II 50 to 77
Moat 2011 TAVR 21 NR NR NR NR
Tamburino 2011 TAVR 15 3 >50% Class I or II NR NR
Thomas 2010, 2011 TAVR TF 19 5 78% Class I or II NR NR
TAVR TA 28 5 69% Class I or II
Zahn 2011 TAVR NR NR NR NR NR
Eggebrecht 2012 TAVR NR 5 NR NR NR
Genereux 2012 TAVR 22 NR NR NR NR
Gilard 2012 TAVR 24 2 90% Class I or II NR NR
Comparative studies
Kapadia 2009 TAVR 22% NR NR NR NR
Medical 44%
Rajani 2010 TAVR 13% NR NR NR NR
Medical 28%
Piazza 2009 TAVR NR NR NR NR NR
Surgical NR NR NR NR NR
Zierer 2009 TAVR 24 NR NR NR NR
Surgical 17 NR NR NR NR
Clavel 2010 TAVR NR NR NR NR NR
Surgical NR NR NR NR NR
Walther 2010 TAVR 27 NR NR NR NR
Surgical 31 NR NR NR NR
Higgins 2011 TAVR NR NR NR NR NR
Surgical NR NR NR NR NR
Stohr 2011 TAVR NR NR NR NR NR
Surgical NR NR NR NR NR
Ben-Dor 2012 TAVR 21 NR NR NR NR
Surgical 21 NR NR NR NR
Medical 36 NR NR NR NR
Conradi 2012 TAVR NR NR NR NR NR
Surgical NR NR NR NR NR
Fusari 2012 TAVR 12 NR 86% Class I or II NR NR
Surgical 10 NR 84% Class I or II NR NR
Jilaihawi 2012 TAVR 23 NR NR NR NR
Surgical 18 NR NR NR NR
Randomized trials
PARTNER B TAVR 31 8 75% Class I or II þ32 þ7
Leon 2010 Medical 50 4 42% Class I or II þ4 þ2
Reynolds 2011
PARTNER A TAVR 24 5 63% Class I or II þ29 þ6.5
Smith 2011 Surgical 27 2 63% Class I or II þ25 þ5.6
Kodali 2012
NYHA, NewYork Heart Association; KCCQ, Kansas City Cardiomyopathy Questionnaire; SF-12, Short Form 12; TAVR, transcatheter aortic valve replacement;NR, not reported;
TF, transfemoral; TA, transapical; PARTNER, Placement of Aortic Transcatheter Valve Trial.
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